Germany Grants National Reimbursement for Three Additional Breast Cancer Biomarker Tests

Germany’s government-funded health insurance will start covering three additional breast cancer biomarker tests that can help doctors and patients decide whether adjuvant chemotherapy after surgery is indicated.

According to an announcement on Thursday by the Federal Joint Committee (G-BA), which makes coverage decisions for Germany’s public health insurance, Myriad Genetics’ EndoPredict, Agendia’s MammaPrint (distributed in Germany by PathoNext), and Veracyte’s Prosigna (developed by NanoString Technologies) will now be covered.

Source: https://www.genomeweb.com/reimbursement-news/germany-grants-national-reimbursement-three-additional-breast-cancer-biomarker